Madrigal Pharmaceuticals, Inc.
MDGL
$424.00
$11.772.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 515.55M | 317.38M | 180.13M | 76.81M | 14.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 515.55M | 317.38M | 180.13M | 76.81M | 14.64M |
| Cost of Revenue | 19.18M | 10.75M | 6.23M | 2.79M | 636.00K |
| Gross Profit | 496.37M | 306.64M | 173.90M | 74.03M | 14.00M |
| SG&A Expenses | 613.54M | 522.13M | 435.06M | 340.37M | 260.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 825.36M | 742.53M | 678.01M | 624.87M | 544.92M |
| Operating Income | -309.81M | -425.15M | -497.87M | -548.05M | -530.28M |
| Income Before Tax | -281.90M | -391.59M | -465.89M | -518.67M | -510.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -281.90 | -391.59 | -465.89 | -518.67 | -510.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -281.90M | -391.59M | -465.89M | -518.67M | -510.45M |
| EBIT | -309.81M | -425.15M | -497.87M | -548.05M | -530.28M |
| EBITDA | -308.40M | -423.84M | -496.78M | -547.18M | -529.57M |
| EPS Basic | -12.85 | -18.04 | -22.11 | -25.07 | -25.50 |
| Normalized Basic EPS | -8.03 | -11.28 | -13.82 | -15.67 | -15.94 |
| EPS Diluted | -12.85 | -18.04 | -22.11 | -25.07 | -25.50 |
| Normalized Diluted EPS | -8.03 | -11.28 | -13.82 | -15.67 | -15.94 |
| Average Basic Shares Outstanding | 87.97M | 87.17M | 85.08M | 82.91M | 79.64M |
| Average Diluted Shares Outstanding | 87.97M | 87.17M | 85.08M | 82.91M | 79.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |